Patrick Whitten, MD
Pulmonary Disease · Peoria, ILNPI 1366438087
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $985 of the $1,633 with a category attached, or 60.3%. Pulmonx Corporation accounts for 82.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $1,210 and has fallen 94.7% since, to $64 in 2025. That places this record below the midpoint for pulmonary disease clinicians in IL, where the typical reported total is $1,325.
Across 20 payments — averaging $81.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$1K
- Jazz Pharmaceuticals Inc.$99
- Covidien LP$58
- Genentech USA, Inc.$38
- AstraZeneca$29
- GSK$21
- plus $37 from 2 others
Across 258 payments — averaging $3142.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$247K
- Galvanize Therapeutics, Inc$232K
- Sanofi US Services Inc.$169K
- Harmony Biosciences LLC$146K
- Astrazeneca UK Limited$16K
What the payments were for
- Travel & lodging$98560%
- Food & beverage$52932%
- Education$1207%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 9 | $1,351 |
| Jazz Pharmaceuticals Inc. | 1 | $99 |
| Covidien LP | 2 | $58 |
| Genentech USA, Inc. | 3 | $38 |
| AstraZeneca | 2 | $29 |
| GSK | 1 | $21 |
| United Therapeutics Corporation | 1 | $21 |
| Boston Scientific | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,633 in reported general payments places this provider in the 50th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,031 | $839,428 |
| XywavSodium,calcium,mag,pot Oxybate | 37 | $621,908 |
| OfevNintedanib Esylate | 37 | $483,452 |
| Spiriva RespimatTiotropium Bromide | 139 | $119,082 |
| Breo ElliptaFluticasone/Vilanterol | 222 | $118,085 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 161 | $113,324 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 112 | $65,156 |
| SymbicortBudesonide/Formoterol Fumarate | 144 | $49,528 |
| Incruse ElliptaUmeclidinium Bromide | 117 | $49,042 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 48 | $30,918 |
| Spiriva HandihalerTiotropium Bromide | 32 | $30,696 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 136 | $26,964 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 686 | $26,533 |
| Arnuity ElliptaFluticasone Furoate | 38 | $18,050 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 129 | $17,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $21 | $1,089,7621,520 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $29 | $183,165353 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Peoria
- Jon MichelPeoria$25K
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Kristopher McDonoughJoliet$461K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Danish ThameemChampaign$353K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.